JP2020514310A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514310A5 JP2020514310A5 JP2019539214A JP2019539214A JP2020514310A5 JP 2020514310 A5 JP2020514310 A5 JP 2020514310A5 JP 2019539214 A JP2019539214 A JP 2019539214A JP 2019539214 A JP2019539214 A JP 2019539214A JP 2020514310 A5 JP2020514310 A5 JP 2020514310A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- use according
- tgf
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023003484A JP7411832B2 (ja) | 2017-01-20 | 2023-01-13 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2023216508A JP7844425B2 (ja) | 2017-01-20 | 2023-12-22 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2025202422A JP2026036696A (ja) | 2017-01-20 | 2025-11-25 | 抗ｔｇｆベータ抗体およびそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448800P | 2017-01-20 | 2017-01-20 | |
| EP17305061 | 2017-01-20 | ||
| US62/448,800 | 2017-01-20 | ||
| EP17305061.8 | 2017-01-20 | ||
| PCT/IB2018/000088 WO2018134681A1 (en) | 2017-01-20 | 2018-01-19 | Anti-tgf-beta antibodies and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023003484A Division JP7411832B2 (ja) | 2017-01-20 | 2023-01-13 | 抗ｔｇｆベータ抗体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514310A JP2020514310A (ja) | 2020-05-21 |
| JP2020514310A5 true JP2020514310A5 (enExample) | 2021-02-18 |
| JP7213186B2 JP7213186B2 (ja) | 2023-01-26 |
Family
ID=61656071
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539214A Active JP7213186B2 (ja) | 2017-01-20 | 2018-01-19 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2023003484A Active JP7411832B2 (ja) | 2017-01-20 | 2023-01-13 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2023216508A Active JP7844425B2 (ja) | 2017-01-20 | 2023-12-22 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2025202422A Pending JP2026036696A (ja) | 2017-01-20 | 2025-11-25 | 抗ｔｇｆベータ抗体およびそれらの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023003484A Active JP7411832B2 (ja) | 2017-01-20 | 2023-01-13 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2023216508A Active JP7844425B2 (ja) | 2017-01-20 | 2023-12-22 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2025202422A Pending JP2026036696A (ja) | 2017-01-20 | 2025-11-25 | 抗ｔｇｆベータ抗体およびそれらの使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10766955B2 (enExample) |
| JP (4) | JP7213186B2 (enExample) |
| CN (2) | CN110520441B8 (enExample) |
| AU (2) | AU2018209391B2 (enExample) |
| BR (1) | BR112019014787A2 (enExample) |
| CA (1) | CA3050845A1 (enExample) |
| CL (1) | CL2019002011A1 (enExample) |
| CO (1) | CO2019008946A2 (enExample) |
| CR (1) | CR20190375A (enExample) |
| DO (1) | DOP2019000191A (enExample) |
| EC (1) | ECSP19059553A (enExample) |
| IL (3) | IL311866B2 (enExample) |
| MA (1) | MA47311A (enExample) |
| MX (2) | MX2019008551A (enExample) |
| MY (1) | MY200751A (enExample) |
| NZ (1) | NZ796440A (enExample) |
| PE (1) | PE20200734A1 (enExample) |
| PH (1) | PH12019501635A1 (enExample) |
| SG (1) | SG11201906660TA (enExample) |
| TW (3) | TWI787230B (enExample) |
| UY (1) | UY37575A (enExample) |
| ZA (1) | ZA201904494B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TWI788321B (zh) | 2017-01-20 | 2023-01-01 | 美商健臻公司 | 骨靶向抗體 |
| CA3105333A1 (en) * | 2018-07-10 | 2020-01-16 | Sanofi | Combination therapies against cancer targeting cd38 and tgf-beta |
| JP7397874B2 (ja) | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| CN120535649A (zh) | 2018-08-30 | 2025-08-26 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| WO2020132647A1 (en) * | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| EP3739588A1 (en) * | 2019-05-13 | 2020-11-18 | Koninklijke Philips N.V. | Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk |
| WO2020257639A1 (en) | 2019-06-21 | 2020-12-24 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CA3169231A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| US12187763B2 (en) | 2020-02-11 | 2025-01-07 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| AU2021220196A1 (en) | 2020-02-11 | 2022-08-04 | HCW Biologics, Inc. | Methods of activating regulatory T cells |
| CN113563473A (zh) | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
| CN112940119B (zh) * | 2021-04-26 | 2022-05-20 | 北京芳渟阳生生物科技有限公司 | 一种单克隆抗体及其与间充质干细胞外泌体的联合应用 |
| WO2022266510A1 (en) * | 2021-06-18 | 2022-12-22 | Genzyme Corporation | Anti-tgf-beta antibody formulations and their use |
| CA3227318A1 (en) | 2021-08-11 | 2023-02-16 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases |
| CN115707716A (zh) * | 2021-08-18 | 2023-02-21 | 丹生医药技术(上海)有限公司 | 一种TGF-β/VEGF双功能抗体融合蛋白 |
| EP4426431A1 (en) * | 2021-11-01 | 2024-09-11 | Genzyme Corporation | Treatment of osteogenesis imperfecta |
| CN119384289A (zh) | 2022-04-13 | 2025-01-28 | 免疫生物公司 | 用于治疗神经炎症性障碍的多链嵌合多肽 |
| AU2023254108B2 (en) | 2022-04-13 | 2026-01-29 | Immunitybio, Inc. | Multi-chain chimeric polypeptide for use in the treatment of circardian clock gene disorder |
| CN115508565B (zh) * | 2022-10-20 | 2024-11-15 | 成都医学院第一附属医院 | Cilp1作为肾纤维化生物标志物的应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| HU230048B1 (hu) | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
| CA2280957A1 (en) | 1997-02-14 | 1998-08-20 | Leslie Orgel | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| ZA988461B (en) | 1997-09-18 | 1999-03-30 | Idec Pharma Corp | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| EP1074563A1 (en) | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
| US20020063763A1 (en) | 2000-11-29 | 2002-05-30 | Mantell David Allen | Apparatus and method for removing air bubbles from an ink jet printhead |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| JP2006523609A (ja) | 2002-12-31 | 2006-10-19 | アルタス ファーマシューティカルズ インコーポレイテッド | タンパク質結晶およびイオン性ポリマーの複合体 |
| US20060286105A1 (en) | 2003-04-30 | 2006-12-21 | Steven Ledbetter | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| WO2005010049A2 (en) | 2003-07-09 | 2005-02-03 | Eli Lilly And Company | Tgf-beta1 ligands |
| CA2561686C (en) * | 2004-03-31 | 2014-12-02 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| PL2348114T3 (pl) | 2004-04-21 | 2019-08-30 | Alexion Pharmaceuticals, Inc. | Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość |
| CN101163502A (zh) | 2005-02-08 | 2008-04-16 | 根茨美公司 | 针对TGFβ的抗体 |
| TW200714289A (en) | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| JP6071165B2 (ja) | 2007-05-31 | 2017-02-01 | ゲンマブ エー／エス | 安定なＩｇＧ４抗体 |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| KR101658247B1 (ko) | 2008-01-03 | 2016-09-22 | 더 스크립스 리서치 인스티튜트 | 모듈 인식 도메인을 통한 항체 표적화 |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| CN102325795B (zh) | 2008-12-22 | 2015-03-25 | 诺沃—诺迪斯克有限公司 | 针对组织因子途径抑制剂的抗体 |
| US20120294868A1 (en) | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
| PT2542590T (pt) | 2010-03-05 | 2017-08-31 | Univ Johns Hopkins | Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| PH12013502489B1 (en) | 2011-06-03 | 2019-04-24 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
| US20130209449A9 (en) | 2011-06-13 | 2013-08-15 | Abgenomics Cooperatief U.A. | Anti-psgl-1 antibodies and uses thereof |
| SG11201401605QA (en) | 2011-10-19 | 2014-09-26 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| WO2013178736A1 (en) | 2012-05-31 | 2013-12-05 | Innate Pharma | Tlr3 binding agents |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CA2886607A1 (en) * | 2012-10-17 | 2014-04-24 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
| SI3312195T1 (sl) * | 2013-03-20 | 2020-02-28 | Genzyme Corporation | Postopki zdravljenja osteogeneze imperfecta |
| HUE052232T2 (hu) | 2013-05-06 | 2021-04-28 | Scholar Rock Inc | Készítmények és eljárások növekedési faktor modulálására |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| SG10202002334PA (en) | 2013-12-17 | 2020-05-28 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| US20170216401A1 (en) | 2014-03-17 | 2017-08-03 | Piotr Jachimczak | Combination for use in a method of treating cancer |
| US20180265874A1 (en) | 2014-10-10 | 2018-09-20 | Global Biopharma, Inc. | Methods for treating and/or preventing a tumor growth, invasion and/or metastasis |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| HK1247861A1 (zh) | 2015-01-30 | 2018-10-05 | President And Fellows Of Harvard College | 用於癌症治疗的肿瘤周围和肿瘤内部材料 |
| TWI733661B (zh) * | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| CN116327915A (zh) * | 2015-04-03 | 2023-06-27 | 佐马技术有限公司 | 使用TGF-β抑制剂和PD-1抑制剂治疗癌症 |
| MY188749A (en) | 2015-04-17 | 2021-12-28 | Bristol Myers Squibb Co | Compositions comprising a combination of nivolumab and ipilimumab |
| WO2017011773A2 (en) | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
| CA2996996A1 (en) | 2015-08-31 | 2017-03-09 | National Research Council Of Canada | Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof |
| WO2018027329A1 (en) | 2016-08-11 | 2018-02-15 | Precithera, Inc. | TGF-β ANTAGONIST CONJUGATES |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TWI788321B (zh) | 2017-01-20 | 2023-01-01 | 美商健臻公司 | 骨靶向抗體 |
-
2018
- 2018-01-18 TW TW107101789A patent/TWI787230B/zh active
- 2018-01-18 TW TW111145565A patent/TWI856437B/zh active
- 2018-01-18 TW TW113140547A patent/TW202506185A/zh unknown
- 2018-01-19 IL IL311866A patent/IL311866B2/en unknown
- 2018-01-19 MX MX2019008551A patent/MX2019008551A/es unknown
- 2018-01-19 IL IL268112A patent/IL268112B2/en unknown
- 2018-01-19 CA CA3050845A patent/CA3050845A1/en active Pending
- 2018-01-19 BR BR112019014787-0A patent/BR112019014787A2/pt unknown
- 2018-01-19 CN CN201880007975.3A patent/CN110520441B8/zh active Active
- 2018-01-19 US US15/875,532 patent/US10766955B2/en active Active
- 2018-01-19 PE PE2019001465A patent/PE20200734A1/es unknown
- 2018-01-19 CN CN202311230922.7A patent/CN117417939A/zh active Pending
- 2018-01-19 AU AU2018209391A patent/AU2018209391B2/en active Active
- 2018-01-19 SG SG11201906660TA patent/SG11201906660TA/en unknown
- 2018-01-19 JP JP2019539214A patent/JP7213186B2/ja active Active
- 2018-01-19 MY MYPI2019003989A patent/MY200751A/en unknown
- 2018-01-19 CR CR20190375A patent/CR20190375A/es unknown
- 2018-01-19 MA MA047311A patent/MA47311A/fr unknown
- 2018-01-19 UY UY0001037575A patent/UY37575A/es not_active Application Discontinuation
- 2018-01-19 NZ NZ796440A patent/NZ796440A/en unknown
-
2019
- 2019-07-09 ZA ZA2019/04494A patent/ZA201904494B/en unknown
- 2019-07-12 PH PH12019501635A patent/PH12019501635A1/en unknown
- 2019-07-17 MX MX2023002588A patent/MX2023002588A/es unknown
- 2019-07-18 CL CL2019002011A patent/CL2019002011A1/es unknown
- 2019-07-19 DO DO2019000191A patent/DOP2019000191A/es unknown
- 2019-08-16 CO CONC2019/0008946A patent/CO2019008946A2/es unknown
- 2019-08-19 EC ECSENADI201959553A patent/ECSP19059553A/es unknown
-
2020
- 2020-07-16 US US16/931,198 patent/US11242384B2/en active Active
-
2021
- 2021-12-23 US US17/561,510 patent/US12049496B2/en active Active
-
2023
- 2023-01-13 JP JP2023003484A patent/JP7411832B2/ja active Active
- 2023-12-22 JP JP2023216508A patent/JP7844425B2/ja active Active
-
2024
- 2024-07-09 US US18/767,270 patent/US20250026821A1/en active Pending
- 2024-11-13 AU AU2024264593A patent/AU2024264593A1/en active Pending
-
2025
- 2025-10-05 IL IL323799A patent/IL323799A/en unknown
- 2025-11-25 JP JP2025202422A patent/JP2026036696A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024037894A5 (enExample) | ||
| JP2020099324A5 (enExample) | ||
| JP2018503365A5 (enExample) | ||
| JP2022510964A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2021531764A5 (enExample) | ||
| JP2020516240A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2018518454A5 (enExample) | ||
| JP2016519650A5 (enExample) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2018508483A5 (enExample) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2017514461A5 (enExample) | ||
| JP2018035138A5 (enExample) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| JP2021531255A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| SI2719708T1 (en) | Material and methods for treating or preventing HER-3-related diseases | |
| JP2010535713A5 (enExample) | ||
| JP2023507190A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2022512851A5 (enExample) | ||
| JP2022516351A5 (enExample) |